RGD Reference Report - Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.

Authors: Weichert, W  Denkert, C  Noske, A  Darb-Esfahani, S  Dietel, M  Kalloger, SE  Huntsman, DG  Kobel, M 
Citation: Weichert W, etal., Neoplasia. 2008 Sep;10(9):1021-7.
RGD ID: 2306205
Pubmed: PMID:18714364   (View Abstract at PubMed)
PMCID: PMC2517648   (View Article at PubMed Central)

Histone deacetylase (HDAC) inhibitors are an emerging class of targeted cancer therapeutics, and little is known about HDAC expression in gynecologic malignancies. Therefore, we tested the hypothesis whether high-level expression of class 1 HDACs (HDAC1, 2, and 3) is associated with clinically distinct subsets of ovarian and endometrial carcinomas. Expression was assessed by immunohistochemistry in a population-based cohort of 465 ovarian and 149 endometrial carcinomas and correlated with clinicopathologic parameters. Each of the HDACs was expressed at high levels in most ovarian (HDAC1, 61%; HDAC2, 93%; HDAC3, 84%) and endometrial (HDAC1, 61%; HDAC2, 95%; HDAC3, 83%) carcinomas. Further, 55% and 56% of ovarian and endometrial carcinomas, respectively, expressed all three HDACs at high levels. Such cases were less common among endometrioid subtypes of ovarian and endometrial carcinomas (36% and 52% positive cases, respectively) compared with high-grade serous subtypes (64 and 69%, respectively, P < .001). High-level expression of all three HDACs is associated with a poor prognosis in ovarian endometrioid carcinomas (hazard ratio, 6.7; 95% confidence interval, 1.9-23.3). The independent prognostic information and the overall high rate of expression for class I HDACs suggest that these targets should be explored as predictive factors in ovarian and endometrial carcinomas prospectively.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
endometrial carcinoma disease_progressionIEP 2306205 RGD 
endometrial carcinoma disease_progressionISOHDAC3 (Homo sapiens)2306205; 2306205 RGD 
Endometrial Neoplasms disease_progressionIEP 2306205; 2306205 RGD 
Endometrial Neoplasms disease_progressionISOHDAC1 (Homo sapiens)2306205; 2306205 RGD 
Endometrial Neoplasms disease_progressionISOHDAC2 (Homo sapiens)2306205; 2306205 RGD 
ovarian carcinoma disease_progressionIEP 2306205 RGD 
ovarian carcinoma disease_progressionISOHDAC3 (Homo sapiens)2306205; 2306205 RGD 
Ovarian Neoplasms disease_progressionIEP 2306205; 2306205 RGD 
Ovarian Neoplasms disease_progressionISOHDAC1 (Homo sapiens)2306205; 2306205 RGD 
Ovarian Neoplasms disease_progressionISOHDAC2 (Homo sapiens)2306205; 2306205 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Hdac1  (histone deacetylase 1)
Hdac2  (histone deacetylase 2)
Hdac3  (histone deacetylase 3)

Genes (Mus musculus)
Hdac1  (histone deacetylase 1)
Hdac2  (histone deacetylase 2)
Hdac3  (histone deacetylase 3)

Genes (Homo sapiens)
HDAC1  (histone deacetylase 1)
HDAC2  (histone deacetylase 2)
HDAC3  (histone deacetylase 3)


Additional Information